HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SGHT
Sight Sciences, Inc.
SGHT lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SGHT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
SGHT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SGHT PE Valuation
SGHT has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SGHT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
SGHT has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SGHT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.51 | +$0.39 |
| Q2 2026 | -$0.55 | +$0.41 |
| Q1 2026 | -$0.70 | +$0.28 |
| Q4 2025 | -$0.74 | +$0.29 |
| Q3 2025 | -$0.90 | +$0.12 |
| Q2 2025 | -$0.96 | +$0.11 |
| Q1 2025 | -$0.98 | +$0.14 |
| Q4 2024 | -$1.03 | +$0.11 |
SGHT has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SGHT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over SGHT on profitability, with a higher operating margin.
SGHT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.9M | +25% |
| Q2 2026 | $23.4M | +20% |
| Q1 2026 | $19.7M | +13% |
| Q4 2025 | $20.4M | +6.9% |
| Q3 2025 | $19.9M | -1.2% |
| Q2 2025 | $19.6M | -8.5% |
| Q1 2025 | $17.5M | -9.1% |
| Q4 2024 | $19.1M | +1.7% |
SGHT's revenue has grown year over year for four quarters in a row: $25M last quarter, up 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -25% | +15 points |
| Q2 2026 | -17% | +43 points |
| Q1 2026 | -63% | +16 points |
| Q4 2025 | -18% | +45 points |
| Q3 2025 | -40% | +16 points |
| Q2 2025 | -60% | -0.4 points |
| Q1 2025 | -79% | -2.7 points |
| Q4 2024 | -63% | -3.3 points |
SGHT's operating margin was −25% last quarter, up 15 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SGHT on cash generation, producing positive trailing cash flow while its opponent burns cash.
SGHT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.5M | +$6.4M |
| Q2 2026 | -$5.7M | +$2.1M |
| Q1 2026 | -$7.1M | +$4.5M |
| Q4 2025 | -$1.7M | +$1.9M |
| Q3 2025 | -$8.9M | -2958% |
| Q2 2025 | -$7.8M | +$1.8M |
| Q1 2025 | -$11.6M | -$1.7M |
| Q4 2024 | -$3.6M | +$3.2M |
SGHT has burned cash in almost every quarter: −$17M over the past year, against −$32M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SGHT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SGHT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +621K shares |
| 1 year | +5.2% | +2.7M shares |
| 3 years | +13% | +6.5M shares |
| 5 years | +474% | +45.5M shares |
| Available history | +57% | +20.1M shares |
SGHT has 55M diluted shares, up 5.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SGHT Net Leverage
SGHT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SGHT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 75.4 | Overbought |
| Stochastic | 91.0 | Overbought |
SGHT's weekly RSI is 75 (overbought) and its Stochastic is 91 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SGHT PE vs Healthcare Sector
SGHT has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SGHT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.25 | 19% above |
| 20 week MA | $7.85 | 40% above |
| 50 week MA | $6.42 | 71% above |
| 100 week MA | $5.07 | 117% above |
| 200 week MA | $5.73 | 92% above |
SGHT has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
SGHT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $32.7 | $18.5 | -43% |
| 2022 | $18.5 | $12.1 | -35% |
| 2023 | $12.1 | $5.16 | -57% |
| 2024 | $5.16 | $3.57 | -31% |
| 2025 | $3.57 | $8.82 | +147% |
| 2026 YTD | $8.82 | $11.0 | +25% |
SGHT has the edge over HIMS on returns for 2026, with the stronger performance.